The claim credit process and conference evaluation will be available online starting Sept. 10 through Dec. 31, 2024, in the IASLC Lung Cancer 360. Log in using your Lung Cancer 360 Username and Password, select the sessions you attended, complete the conference evaluation, and download your certificate. If you are new to Lung Cancer 360 or forgot your password, click the Reset Password link.

For assistance, please email [email protected].

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 107.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians.

• Antigua & Barbuda
  REGULATOR
  Antigua & Barbuda Medical Council
• Austria
  REGULATOR
  Austrian Academy of Physicians on behalf of the Austrian Medical Chamber
• Bahamas
  REGULATOR
  Bahamas Medical Council
• Belgium
  REGULATOR
  Group of Belgian Professional Unions of Specialist Doctors
• Bhutan
  REGULATOR
  Medical and Health Professional Council, Royal Government of Bhutan
• Croatia
  REGULATOR
  Croatian Medical Chamber
• Gambia, The
  REGULATOR
  The Medical and Dental Council of the Gambia
• Germany
  REGULATOR
  State Chambers of Physicians in the 16 federal states
  (only in-person, live events)
• India, State of Punjab
  REGULATOR
  Punjab Medical Council
• Israel
  REGULATOR
  Scientific Council, Israeli Medical Association
• Jamaica
  REGULATOR
  Medical Council of Jamaica
• Kuwait
  REGULATOR
  Professional Licensing – Ministry of Health
• Malawi
  REGULATOR
  Medical Council of Malawi
• Netherlands, The
  REGULATOR
  Royal Dutch Society of the Promotion of Medicine
• Oman
  REGULATOR
  Oman Medical Specialty Board
• Qatar
  REGULATOR
  Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health
• Rwanda
  REGULATOR
  Rwanda Medical & Dental Council
• Saudi Arabia
  REGULATOR
  Saudi Commission for Health Specialties
• Singapore
  REGULATOR
  Singapore Medical Council
• South Africa
  REGULATOR
  Health Professions Council of South Africa
• Spain
  REGULATOR
  Spanish Medical Professional Accreditation Council for CPD/CME
• Sri Lanka
  REGULATOR
  Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health
• Sweden
  REGULATOR
  Swedish Medical Association
• Trinidad & Tobago
  REGULATOR
  The Trinidad and Tobago Medical Association
• Turkey
  REGULATOR
  Turkish Medical Association CME-CPD Accreditation Council
• United Arab Emirates, Abu Dhabi
  REGULATOR
  Department of Health
• United Arab Emirates, Dubai
  REGULATOR
  Dubai Health Authority

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities. 

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity. 

All disclosures will be available to participants via the conference app and on the conference website.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.

The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2024 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.

The IASLC 2024 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

At the conclusion of this activity, participants will be able to: 

• Synthesize cutting-edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
• Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage thoracic malignancies.
• Collaborate on multidisciplinary teams to improve patient diagnostic, therapeutic, and palliative care through an equitable, quality, and value lens.
• Engage and empower patients to become active participants in their treatment. 
• Illustrate the importance of scientific advances in the epidemiology and biology of thoracic cancer that have the potential to lead to impactful outcomes for patients and the public.
• Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and broader implementation of low-dose CT screening programs worldwide.

The official language of the IASLC 2024 World Conference on Lung Cancer is English.